Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1786 to 1800 of 7707 results

  1. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592

    Awaiting development [GID-TA11332] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over TS ID 9130

    Awaiting development [GID-TA11325] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Galcanezumab for migraine TS ID 10663

    Awaiting development [GID-TA11311] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Infection prevention and control update

    In development [GID-QS10177] Expected publication date: TBC

    Quality standard
    In development

  5. Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 TS ID 10767

      Status ...

    Technology appraisal guidance
    Topic selection

  6. SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

    In development [GID-MT526] Expected publication date: TBC

    Medical technologies guidance
    In development

  7. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    In development [GID-TA10764] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Managing common infections - antimicrobial prescribing guidelines

    In development [GID-NG10050] Expected publication date: TBC

    NICE guideline
    In development

  9. Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

    Awaiting development [GID-TA10431] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over TS ID 11777

    Awaiting development [GID-TA11292] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Subcutaneous efgartigmod for treating generalised myasthenia gravis TS ID 11835

      Status ...

    Technology appraisal guidance
    Topic selection

  12. Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 TS ID 10730

    Awaiting development [GID-TA11105] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. CT-P39 (omalizumab biosimilar) for previously treated chronic spontaneous urticaria TS ID 11832

      Status ...

    Technology appraisal guidance
    Topic selection

  14. WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467

    Awaiting development [GID-TA11305] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Perioperative care

    Awaiting development [GID-QS10094] Expected publication date: TBC

    Quality standard
    Awaiting development